Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbbVie

184.85
-4.4100-2.33%
Post-market: 185.600.7500+0.41%19:59 EDT
Volume:4.95M
Turnover:923.01M
Market Cap:326.52B
PE:79.00
High:189.90
Open:189.62
Low:184.63
Close:189.26
Loading ...

AbbVie Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
06 May

Top Midday Stories: Trump Vows 100% Tariff on Foreign-Made Films; Buffett to Step Down As Berkshire CEO

MT Newswires Live
·
06 May

Market Chatter: India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs

MT Newswires Live
·
05 May

Trump Says Drug Tariffs Are Coming. Big Pharma Execs Can't Figure Out How Much to Worry. -- Barrons.com

Dow Jones
·
03 May

Cigna raises full-year profit forecast, latest to beat medical cost estimates

Reuters
·
02 May

Transforming HR Leadership: Inside The Darla Moore School’s Standout MHR Program

Poets & Quants
·
02 May

High Growth Tech Stocks In The US Market April 2025

Simply Wall St.
·
30 Apr

Moderna (MRNA) Reports Earnings Tomorrow: What To Expect

StockStory
·
30 Apr

Amgen (AMGN) Reports Earnings Tomorrow: What To Expect

StockStory
·
30 Apr

Biogen Earnings: What To Look For From BIIB

StockStory
·
30 Apr

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings

StockStory
·
30 Apr

BRIEF-RINVOQ (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

Reuters
·
29 Apr

Guggenheim Adjusts AbbVie Price Target to $216 From $214, Maintains Buy Rating

MT Newswires Live
·
29 Apr

Rinvoq® (Upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (Gca)

THOMSON REUTERS
·
29 Apr

United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect

StockStory
·
29 Apr

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (IRWD), AbbVie (ABBV) and Molecular Partners (MOLN)

TIPRANKS
·
29 Apr

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

Reuters
·
29 Apr

AbbVie Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
28 Apr

AbbVie price target raised to $227 from $220 at Raymond James

TIPRANKS
·
28 Apr

Raymond James Adjusts Price Target on AbbVie to $227 From $220, Maintains Outperform Rating

MT Newswires Live
·
28 Apr